An outcome-led commitment in RARE
OPEN Health is highly invested in the delivery of positive outcomes in rare disease. Having worked with many clients within the area of orphan and ultra-orphan medicine, we have the experience to recognize that every scenario is unique. With our extensive experience across practices, we are able to craft bespoke, cohesive solutions to achieve optimal outcomes for our clients and the rare disease patients they serve.
Leading our commitment in RARE
To optimize our capabilities and truly meet or exceed customers’ needs, we have invested in a Global Advisory Rare Diseases to work across all our practices.
Gavin Jones has over 20 years of biopharmaceutical industry experience across numerous roles concerned with market access, therapy launch, and patient-centric services. For 15 years, he has developed a specialist interest in rare and ultra-rare disease supporting many orphan therapies as they have been commercialized. He is passionate about supporting optimal patient outcomes through effective therapy awareness, diagnostic and treatment pathway improvement, and patient activation.
A proud partner of Rare Revolution magazine
We always strive for a ‘patient-first’ approach in rare disease, and we are therefore honored to be partnered with Rare Revolution magazine.
We value the opportunity to share our thoughts on important topics in rare disease and contribute to the magazine’s mission of amplifying the patient voice in rare disease.
Read the articles
Our thinking in rare blood
After many years of creeping evolution, we now are in the midst of rapid evolution in the management of hemophilia and other rare blood disorders. We look at how Pharma supports more personalized approaches to managing these conditions in a way that enables patients to live more freely with their condition while feeling protected from adverse events.
Our thinking in rare oncology
At a time of increased innovation in diagnostics and the growth of more personalized medicine, rare cancers may seem to be more common. We discuss how communications can be effectively delivered to support better outcomes for patients living with rare and less common cancers.
Our thinking in gene therapy
It is a fascinating time; we are moving from a trickle of gene and advanced cell therapies to a potential torrent of new treatments coming to market. This is going to create unprecedented challenges and opportunities and world-class communications will be required to maximise their potential.
Patients as Partners
Patient-centricity continues to grow in priority within Bio-Pharma’s clinical and commercial strategies. Given the high stakes and continued unmet need, rare disease communities should help lead effective patient partnerships that remain compliant and sustainable. We share our ‘patient first’ thinking here.
Professionals and Places
In these challenging times, the rare disease community must draw closer than ever and harness efforts to improve outcomes for patients and families living with a rare disease. We look at how to harness this collective power and create connectivity between key stakeholders to deliver better outcomes for patients.
Patient Transition
Given improvements in disease management, children and adolescents with rare diseases are living longer. Underneath this positivity is the challenge of effectively supporting these patients into adulthood. We will consider the challenges in transition and how Pharma can support patients as they transition from pediatric into adult services.
